| Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. | |
| | |
MedLine Citation:
|
PMID: 21115908 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To determine if the drug doses and administration schedules of carboplatin and gemcitabine combination affect antitumor effects. MATERIALS AND METHODS: The inhibition of cell viability was measured by MTT assay. Median effect analysis was conducted to determine the cytotoxicity activity of carboplatin and gemcitabine combination. Cell cycle changes were analyzed by flow cytometry. RESULTS: Synergism was observed when the bladder cancer cell line 5637 cells were treated with gemcitabine followed by carboplatin or concurrent carboplatin/gemcitabine. In contrast, moderate antagonism was observed when cells were treated with carboplatin followed by gemcitabine. Cell cycle analysis showed that the combined effect of these two drugs was cell cycle disturbance. CONCLUSION: Different doses and administration schedules affect the antitumor effect of carboplatin/gemcitabine combination that may have clinical significance in the treatment for bladder cancer. |
| | |
Authors:
|
Sisi Wang; Hongyong Zhang; Liang Cheng; Christopher Evans; Chong-Xian Pan |
Related Documents
:
|
16481748 - The transcriptional co-repressor c-terminal binding protein (ctbp) associates with cent... 2163768 - A protein factor, asf, controls cell-specific alternative splicing of sv40 early pre-mr... 12907668 - Hmga1 co-activates transcription in b cells through indirect association with dna. 21416478 - In vitro toxicity of aflatoxin b(1) and its photodegradation products in hepg2 cells. 15390108 - Shaker-type potassium channel subunits differentially control oligodendrocyte progenito... 16465228 - Cell death in the gastrulating chick embryo: potential roles for tumor necrosis factor-... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Anticancer research Volume: 30 ISSN: 1791-7530 ISO Abbreviation: Anticancer Res. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-30 Completed Date: 2011-01-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8102988 Medline TA: Anticancer Res Country: Greece |
Other Details:
|
Languages: eng Pagination: 4573-8 Citation Subset: IM |
Affiliation:
|
Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Cancer Center, Sacramento, CA 95817, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
pharmacology* Carboplatin / administration & dosage Cell Cycle / drug effects* Cell Line, Tumor Cell Proliferation / drug effects* Deoxycytidine / administration & dosage, analogs & derivatives Drug Synergism Flow Cytometry Humans Tumor Cells, Cultured Urinary Bladder Neoplasms / drug therapy*, pathology |
| Grant Support | |
ID/Acronym/Agency:
|
UL1 RR024146/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
103882-84-4/gemcitabine; 41575-94-4/Carboplatin; 951-77-9/Deoxycytidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: LOXL4 as a selective molecular marker in primary and metastatic head/neck carcinoma.
Next Document: EGF-dependent induction of BCL-xL and p21CIP1/WAF1 is highly variable in HNSCC cells--implications f...